Technical Analyst, Vermilion Research

Joe Jasper

Technical Analyst

Technical and Quantitative Research

Vermilion Research

Vermilion’s objective is to deliver timely, actionable, and unique technical research to professional investors through the application of our various technical indicators.

Our research strategists seek to highlight securities which we believe are at major inflection points, based on our various technical and quantitative indicators, and offer asymmetric risk/return profiles. Our unique research methodology, centered on relative strength, enables our strategists to deliver superior investment recommendations.

Our process begins by organizing the universe of actively traded stocks into discrete sectors, then into industry groups. We then apply our technical and quantitative tools to identify developing price trends. Once attractive trends are identified within a selected sector or group, we screen for individual stocks which we believe offer the best risk/reward profile. We provide a historical perspective that often reveals, through our long-term charts, how price patterns often repeat themselves over time.

Technical Analysis

MSCI Emerging Markets Index / Technical Analysis

The laundry list of current market conditions consistent with the profile of a bull market continues to grow, helping support our ongoing belief that global equities are in the early stages of a broad-based advance. We explore and highlight actionable investment themes and opportunities across the EM space and within materials, Energy, Manufacturing, Health care and Apparel/Luxury Goods

The laundry list of current market conditions consistent with the profile of a bull market continues to grow, helping support our ongoing belief that global equities are in the early stages of a broad-based advance. We explore and highlight actionable investment themes and opportunities across the EM space and within materials, Energy, Manufacturing, Health care and Apparel/Luxury Goods

Global equities remain in a short-term consolidation phase, however we continue to believe the longer-term trend is up and to the right for the MSCI ACWI following the late-October breakout.  In this report we recap important technical levels across all major indexes and highlight actionable opportunities within Global Health Care stocks, which are hitting on all cylinders, with plenty of opportunities across various industries (services, devices/equipment, pharmaceuticals, biotech, etc.) and geographies (Europe, Japan, China, EM, etc.).

Global equities remain in a short-term consolidation phase, however we continue to believe the longer-term trend is up and to the right for the MSCI ACWI following the late-October breakout.  In this report we recap important technical levels across all major indexes and highlight actionable opportunities within Global Health Care stocks, which are hitting on all cylinders, with plenty of opportunities across various industries (services, devices/equipment, pharmaceuticals, biotech, etc.) and geographies (Europe, Japan, China, EM, etc.).

Global Equity Strategy: Health Care Hitting On All Cylinders - Overweight

Despite negative recent developments, we have remained steadfast in our belief that weakness in May has presented an attractive time to add exposure. In our June International Strategy, we highlight various themes which lead to this belief, along with areas of the market where we see actionable opportunities within our favorite Groups, spanning the Consumer Staples, Technology, Consumer Discretionary, Services, Health Care, and Financial Sectors.

Despite negative recent developments, we have remained steadfast in our belief that weakness in May has presented an attractive time to add exposure. In our June International Strategy, we highlight various themes which lead to this belief, along with areas of the market where we see actionable opportunities within our favorite Groups, spanning the Consumer Staples, Technology, Consumer Discretionary, Services, Health Care, and Financial Sectors.

Global Ex-U.S. Equity Strategy: Cautiously Optimistic Outlook Intact

Developed international equities (MSCI EAFE) have been underperforming relative to global equities (MSCI ACWI). However, within EAFE, SMID-caps tell a different story and are a great source of investment ideas within the EAFE region. In today’s report we use a bottom-up approach to highlight actionable charts, sorted by market cap (all buys at current levels).

Developed international equities (MSCI EAFE) have been underperforming relative to global equities (MSCI ACWI). However, within EAFE, SMID-caps tell a different story and are a great source of investment ideas within the EAFE region. In today’s report we use a bottom-up approach to highlight actionable charts, sorted by market cap (all buys at current levels).

Korea / Special Sits, Pairs, Index Rebalancing, Clepsydra Capital

Sanghyun Park

Korea / Special Sits, Pairs, Index Rebalancing

Equity Capital Markets

Samyang Optics Co. / Equity Capital Markets

<a href="https://www.smartkarma.com/entities/24100" target="_blank" data-smartkarma-citation="entities:24100:1">Samyang Optics Co. Ltd (225190 KS)</a> IPO price was set at ₩16,700, which is the lowest level of the indicative price band (₩16,700 - ₩20,600), after conducting the demand survey (May 18-19) from the institutional investors. The subscription competition rate is 33.2 to 1. A total of 311 local and overseas institutional investors have participated in this demand survey. Foreign investment institutions accounted for 16.7% in terms of share placement qty and 27.7% in terms of participating…

Samyang Optics Co. Ltd (225190 KS) IPO price was set at ₩16,700, which is the lowest level of the indicative price band (₩16,700 - ₩20,600), after conducting the demand survey (May 18-19) from the institutional investors. The subscription competition rate is 33.2 to 1. A total of 311 local and overseas institutional investors have participated in this demand survey. Foreign investment institutions accounted for 16.7% in terms of share placement qty and 27.7% in terms of participating…

Samyang Optics IPO Part 2 - IPO Bookbuilding Results

Germany

Carl Zeiss Meditec AG provides complete system solutions in the field of medical technology for ophthalmology.  The Company's products include screening, diagnostic, and therapeutic systems for the treatment of vision defects, cataracts, glaucoma, and retinal disorders.  Carl Zeiss Meditec operates worldwide with subsidiaries in the USA and Japan.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Carl Zeiss Meditec (AFX GR)

EM Breakout -- Add Exposure

The laundry list of current market conditions consistent with the profile of a bull market continues to grow, helping support our ongoing belief...

Vermilion Research

Global Equity Strategy: Health Care Hitting On All Cylinders - Overweight

Global equities remain in a short-term consolidation phase, however we continue to believe the longer-term trend is up and to the right for the...

Vermilion Research

Global Ex-U.S. Equity Strategy: Cautiously Optimistic Outlook Intact

Despite negative recent developments, we have remained steadfast in our belief that weakness in May has presented an attractive time to add...

Vermilion Research

Focus on Outperforming EAFE SMID-Caps

Developed international equities (MSCI EAFE) have been underperforming relative to global equities (MSCI ACWI). However, within EAFE, SMID-caps...

Vermilion Research

Samyang Optics IPO Part 2 - IPO Bookbuilding Results

Samyang Optics Co. Ltd (225190 KS) IPO price was set at ₩16,700, which is the lowest level of the indicative price band (₩16,700 - ₩20,600), after...

Sanghyun Park

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)